Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.

PHASE4CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

October 9, 2024

Study Completion Date

October 9, 2024

Conditions
Cutis Laxa FacialisXeroderma
Interventions
DEVICE

HydraFacial Syndeo System

Utilizing patented Vortex Fusion Technology, a pneumatic device, the HydraFacial Syndeo system cleanses, exfoliates, and hydrates the skin.

DRUG

ReGen-GF

The Regen-GF Booster, a serum formulated to increase collagen and elastin production, will be used during each HydraFacial treatment using the HydraFacial handpiece and specialized tip for application. Ingredients include Heptapeptide-32 maintains the appearance of healthy, youthful skin through collagen and elastin production, Copper Peptide Cu-GHK regenerates healthy-looking skin by accelerating wound healing and skin repair, Palmitoyl Tetrapeptide-7 treats inflammation while boosting the growth of collagen-producing tissues, Palmitoyl Tripeptide-5 helps skin cells flush toxins while enhancing the appearance of firmness, Azelaoyl Bis-Dipeptide 10 addresses signs of aging by managing the formation of free radicals, K3 Vitamin C promotes collagen synthesis, and Hyaluronic Acid hydrates the skin.

DEVICE

HydraFacial Elite MD System

Utilizing patented Vortex Fusion Technology, the HydraFacial Elite MD system cleanses, exfoliates, and hydrates the skin.

Trial Locations (2)

77056

Austin Institute for Clinical Research, Inc., Houston

78660

Austin Institute for Clinical Research, Inc., Pflugerville

All Listed Sponsors
collaborator

The HydraFacial Company

UNKNOWN

lead

Austin Institute for Clinical Research

NETWORK